TY - JOUR
T1 - Clinicopathological features of 171 cases of primary thyroid lymphoma
T2 - A long-term study involving 24553 patients with Hashimoto's disease
AU - Watanabe, Natsuko
AU - Noh, Jaeduk Y.
AU - Narimatsu, Hiroto
AU - Takeuchi, Kengo
AU - Yamaguchi, Takuhiro
AU - Kameyama, Kaori
AU - Kobayashi, Kazuhiko
AU - Kami, Masahiro
AU - Kubo, Atsushi
AU - Kunii, Yo
AU - Shimizu, Taeko
AU - Mukasa, Koji
AU - Otsuka, Fumiko
AU - Miyara, Ayako
AU - Minagawa, Akinobu
AU - Ito, Koichi
AU - Ito, Kunihiko
PY - 2011/4
Y1 - 2011/4
N2 - There are few large-scale reports of primary thyroid lymphoma (PTL). This study clinically and pathologically reviewed 171 patients with PTL and 24553 patients with Hashimoto's disease at Ito Hospital between January 1990 and December 2004, to investigate the clinical features and the treatment outcomes of PTL. The median age of the patients with PTL was 67years (range, 27-90years). The pathological diagnosis of PTL patients included diffuse large B-cell lymphoma (DLBCL) (n=74), DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma (n=13), MALT lymphoma (n=80) and others (n=4). Of the 167 patients with B-cell lymphoma, treatment included combined modality therapy (CMT) (n=95), radiation therapy (RT) alone (n=60) and chemotherapy alone (n=6). Information on treatment was not available in six patients. Information on treatment response was available in 154 patients; 149 patients (97%) responded to treatment. According to the institutional treatment strategy of Ito Hospital, 45 of 54 patients with stage IE disease received RT alone, and 87 of 113 stage IIE patients received CMT. The 5-year overall survival rate was 85% (95% confidence interval, 79-91%). This study demonstrated that PTL showed good response to radiotherapy and chemotherapy and had a favourable prognosis.
AB - There are few large-scale reports of primary thyroid lymphoma (PTL). This study clinically and pathologically reviewed 171 patients with PTL and 24553 patients with Hashimoto's disease at Ito Hospital between January 1990 and December 2004, to investigate the clinical features and the treatment outcomes of PTL. The median age of the patients with PTL was 67years (range, 27-90years). The pathological diagnosis of PTL patients included diffuse large B-cell lymphoma (DLBCL) (n=74), DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma (n=13), MALT lymphoma (n=80) and others (n=4). Of the 167 patients with B-cell lymphoma, treatment included combined modality therapy (CMT) (n=95), radiation therapy (RT) alone (n=60) and chemotherapy alone (n=6). Information on treatment was not available in six patients. Information on treatment response was available in 154 patients; 149 patients (97%) responded to treatment. According to the institutional treatment strategy of Ito Hospital, 45 of 54 patients with stage IE disease received RT alone, and 87 of 113 stage IIE patients received CMT. The 5-year overall survival rate was 85% (95% confidence interval, 79-91%). This study demonstrated that PTL showed good response to radiotherapy and chemotherapy and had a favourable prognosis.
KW - Chemotherapy
KW - Clinical stage
KW - Diffuse large B-cell lymphoma
KW - Irradiation
KW - Mucosa-associated-lymphoid tissue
UR - http://www.scopus.com/inward/record.url?scp=79953078052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953078052&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2011.08606.x
DO - 10.1111/j.1365-2141.2011.08606.x
M3 - Article
C2 - 21371004
AN - SCOPUS:79953078052
SN - 0007-1048
VL - 153
SP - 236
EP - 243
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 2
ER -